875), the SEN and SPE was 82.5% and 81.2%. The YI, SEN, SPE, and AUC for RDWI were 62.8%, 79.1%, 83.7%, and 0.870, respectively. The formulas of Green and King and RDWI can be used for the differential diagnosis of TT and IDA, suitable for chidren in Shenzhen, China. The formulas of Green and King and RDWI can be used for the differential diagnosis of TT and IDA, suitable for chidren in Shenzhen, China. To compare the clinical efficacy between frontline haplo-identical hematopoietic stem cell transplantation (haplo-HSCT) and salvage haplo-HSCT for patients with severe aplastic anemia (SAA). A total of 39 patients with severe aplastic anemia or very severe aplastic anemia from May 1st, 2013 to December 31st, 2018 were analyzed retrospectively. All of them underwent bone marrow + peripheral blood hemopoietic stem cell transplantation. There were 20 cases who accepted frontline haplo-HSCT for a median course of 1 (1-3) month, and 19 cases who accepted salvage haplo-HSCT for a median course of 72 (6-168) months. Conditioning regimen 22 cases received Flu/Cy+ATG, and 17 cases received Bu/Cy+ATG. The time of hematopoietic reconstitution, infection rate, and grade I-Ⅱ and Ⅲ-Ⅳ acute/chronic graft versus host disease showed no statistically significance between the frontline haplo-HSCT group and the salvage haplo-HSCT group. In the frontline haplo-HSCT group, 1 case (5%) failed in second engraftment, in the salvage haplo-HSCT group 2 cases (10.5%) failed in primary engraftment and 4 cases (21.1%) in second engraftment. The incidence of engraftment failure was higher in the salvage haplo-HSCT group than that in the frontline haplo-HSCT group (P=0.04). The median time of follow-up after allo-HSCT was 45 months (ranging from 3 to 92). The mortality was 10% (2/20) in the frontline haplo-HSCT group, and 42.1% (8/19) in the salvage haplo-HSCT group. The estimated 5-year failure-free survival rate (FFS) of the frontline haplo-HSCT group was higher than that of the salvage haplo-HSCT group (90% vs 57.4%) (P=0.02). The frontline haplo-HSCT is an effective and safe approach for the patients with severe aplastic anemia who lack a HLA-matched sibling donor. The frontline haplo-HSCT is an effective and safe approach for the patients with severe aplastic anemia who lack a HLA-matched sibling donor. To investigate the values of mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), red cell osmotic fragility test(ROFT) and hemoglobin A2(HbA ) in screening of α-thalassemia in Guangdong area. A total of 285 peripheral blood samples in patients treated in our hospital from January 2017 to December 2017 were collected. The detection of thalassemia gene was used as the gold standard, while blood routine examination, hemoglobin electrophoresis, and red cell osmotic fragility test were simultaneously performed. The optimal cut-off values in MCV, MCH, ROFT and HbA in α-thalassemia were determined by receiver operator characteristic curve (ROC curve). The most common types of α-thalassemia gene was --SEA/αα (54.59%). https://www.selleckchem.com/ Compared with the control group, the differences in MCV, MCH, ROFT and HbA showed statistically significantce between different types of α-thalassemia (P<0.05). The best cut-off values of MCV, MCH, ROFT, and HbA in the diagnosis of α-thalassemia were 81.45 fl, 27.35 pg, 79.95%, and 2.55% respectively. For different laboratories, the cut-off values need to be established for screening α-thalassemia suitable in their own local region．The values of MCV, MCH, ROFT and HbA shows higher accuracy and sensitivity in the diagnosis of α-thalassemia. It is recommended to use MCV<81.45fl, MCH<27.35 pg, ROFT<79.95% and HbA <2.55% as the standards for screening α-thalassemia in Guangdong area. For different laboratories, the cut-off values need to be established for screening α-thalassemia suitable in their own local region．The values of MCV, MCH, ROFT and HbA2 shows higher accuracy and sensitivity in the diagnosis of α-thalassemia. It is recommended to use MCV less then 81.45fl, MCH less then 27.35 pg, ROFT less then 79.95% and HbA2 less then 2.55% as the standards for screening α-thalassemia in Guangdong area. To explore the correlation between the of regulatory T cells, Th17 cells and the prognosis of children with aplastic anemia. The clinical data 13 children with aplastic anemia (AA) treated by antithymocyte globulin (ATG) combined with Cyclosporine in Beijing Children's Hospital, Capital Medical University from January 2017 to January 2018 were analyized retrospectively. The changes of T cell and Th17 cell expression level in peripheral blood of AA children before and after IST for 6 and 12 month were compared and analyzed. The SPSS 19.0 statistical package was used for data analysis. Compared with the pre-IST, the expression level of Treg cells decreased at 6 months of IST, the difference was statistically significant (P＜0.05); however the expression level of Th17 cells did not show significant difference as compared with that pre-IST. The expression level of Treg and Th17 cells at 12 months of IST was lower than that pre-IST (P＜0.01), compared with the level pre-IST, the ratio of Treg cells/Th17 cell at 6 months and 12 months of IST did not show a singificand difference. Treg cells and Th17 cells in peripheral blood of AA children decrease after IST, which suggests that the change of regulatory T cells and Th17 cells correlate with the clinical outcome of children with aplastic anemia. Treg cells and Th17 cells in peripheral blood of AA children decrease after IST, which suggests that the change of regulatory T cells and Th17 cells correlate with the clinical outcome of children with aplastic anemia. To investigate the difference of clinical characteristics between young patients(age≤40 years old) and middle-older patients(age>40 years old) with the myeloproliferative neoplasms（MPN）. The clinical data (gene mutations， peripheral blood routine examinations， imaging examination and past history) of 269 MPN patients was collected and analyzed. In essential thrombocythemia (ET) group, the proportion of triple-negative type in young patients was higher than that in middle-older group, while the peripheral white blood cell（WBC） and platelets（PLT） counts in the first visit were lower. In polycythemia vera (PV) group, the total detection rate of JAK2V617F (80.65%) was lower than that of other research reports. Young patients with PV showed the lower JAK2V617F rate and lower WBC count, compared with the middle-older aged patients. Both CALR and MPL mutations were not found in PV patients. There was only 1 primary myelofibrosis (PMF) patient aged <40 years old. 91.67% of the patients merged splenomegaly and this rate was higher than that of ET or PV patients.